Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

GBD 2016 Parkinson’s Disease Collaborators

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. Methods: Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. Findings: In 2016, 6·1 million (95% uncertainty interval [UI] 5·0–7·3) individuals had Parkinson's disease globally, compared with 2·5 million (2·0–3·0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21·7% (95% UI 18·1–25·3) over the same period (compared with an increase of 74·3%, 95% UI 69·2–79·6, for crude prevalence rates). Parkinson's disease caused 3·2 million (95% UI 2·6–4·0) DALYs and 211 296 deaths (95% UI 167 771–265 160) in 2016. The male-to-female ratios of age-standardised prevalence rates were similar in 2016 (1·40, 95% UI 1·36–1·43) and 1990 (1·37, 1·34–1·40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. Interpretation: Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially. Funding: Bill & Melinda Gates Foundation.

Original languageEnglish
Pages (from-to)939-953
Number of pages15
JournalThe Lancet Neurology
Volume17
Issue number11
DOIs
Publication statusPublished - 1 Nov 2018

Fingerprint

Parkinson Disease
Uncertainty
Quality-Adjusted Life Years
Demography
Oceania
Global Burden of Disease
Eastern Europe
Latin America
Mortality
Life Expectancy
Nervous System Diseases
Natural History
Neurodegenerative Diseases
Fertility
Epidemiologic Studies
Public Health
Education
Weights and Measures

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Global, regional, and national burden of Parkinson's disease, 1990–2016 : a systematic analysis for the Global Burden of Disease Study 2016. / GBD 2016 Parkinson’s Disease Collaborators.

In: The Lancet Neurology, Vol. 17, No. 11, 01.11.2018, p. 939-953.

Research output: Contribution to journalArticle

@article{2b40acdb5ccd497296c2c3035f36f657,
title = "Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016",
abstract = "Background: Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. Methods: Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. Findings: In 2016, 6·1 million (95{\%} uncertainty interval [UI] 5·0–7·3) individuals had Parkinson's disease globally, compared with 2·5 million (2·0–3·0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21·7{\%} (95{\%} UI 18·1–25·3) over the same period (compared with an increase of 74·3{\%}, 95{\%} UI 69·2–79·6, for crude prevalence rates). Parkinson's disease caused 3·2 million (95{\%} UI 2·6–4·0) DALYs and 211 296 deaths (95{\%} UI 167 771–265 160) in 2016. The male-to-female ratios of age-standardised prevalence rates were similar in 2016 (1·40, 95{\%} UI 1·36–1·43) and 1990 (1·37, 1·34–1·40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. Interpretation: Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially. Funding: Bill & Melinda Gates Foundation.",
author = "{GBD 2016 Parkinson’s Disease Collaborators} and {Ray Dorsey}, E. and Alexis Elbaz and Emma Nichols and Foad Abd-Allah and Ahmed Abdelalim and Adsuar, {Jose C.} and Ansha, {Mustafa Geleto} and Carol Brayne and Choi, {Jee Young J.} and Daniel Collado-Mateo and Nabila Dahodwala and Do, {Huyen Phuc} and Dumessa Edessa and Matthias Endres and Fereshtehnejad, {Seyed Mohammad} and Foreman, {Kyle J.} and Gankpe, {Fortune Gbetoho} and Rahul Gupta and Hankey, {Graeme J.} and Hay, {Simon I.} and Hegazy, {Mohamed I.} and Hibstu, {Desalegn T.} and Amir Kasaeian and Yousef Khader and Ibrahim Khalil and Khang, {Young Ho} and Kim, {Yun Jin} and Yoshihiro Kokubo and Giancarlo Logroscino and Jo{\~a}o Massano and {Mohamed Ibrahim}, Norlinah and Mohammed, {Mohammed A.} and Alireza Mohammadi and Maziar Moradi-Lakeh and Mohsen Naghavi and Nguyen, {Binh Thanh} and Nirayo, {Yirga Legesse} and Ogbo, {Felix Akpojene} and Owolabi, {Mayowa Ojo} and Pereira, {David M.} and Postma, {Maarten J.} and Mostafa Qorbani and Rahman, {Muhammad Aziz} and Roba, {Kedir T.} and Hosein Safari and Saeid Safiri and Maheswar Satpathy and Monika Sawhney and Azadeh Shafieesabet and Shiferaw, {Mekonnen Sisay}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/S1474-4422(18)30295-3",
language = "English",
volume = "17",
pages = "939--953",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "11",

}

TY - JOUR

T1 - Global, regional, and national burden of Parkinson's disease, 1990–2016

T2 - a systematic analysis for the Global Burden of Disease Study 2016

AU - GBD 2016 Parkinson’s Disease Collaborators

AU - Ray Dorsey, E.

AU - Elbaz, Alexis

AU - Nichols, Emma

AU - Abd-Allah, Foad

AU - Abdelalim, Ahmed

AU - Adsuar, Jose C.

AU - Ansha, Mustafa Geleto

AU - Brayne, Carol

AU - Choi, Jee Young J.

AU - Collado-Mateo, Daniel

AU - Dahodwala, Nabila

AU - Do, Huyen Phuc

AU - Edessa, Dumessa

AU - Endres, Matthias

AU - Fereshtehnejad, Seyed Mohammad

AU - Foreman, Kyle J.

AU - Gankpe, Fortune Gbetoho

AU - Gupta, Rahul

AU - Hankey, Graeme J.

AU - Hay, Simon I.

AU - Hegazy, Mohamed I.

AU - Hibstu, Desalegn T.

AU - Kasaeian, Amir

AU - Khader, Yousef

AU - Khalil, Ibrahim

AU - Khang, Young Ho

AU - Kim, Yun Jin

AU - Kokubo, Yoshihiro

AU - Logroscino, Giancarlo

AU - Massano, João

AU - Mohamed Ibrahim, Norlinah

AU - Mohammed, Mohammed A.

AU - Mohammadi, Alireza

AU - Moradi-Lakeh, Maziar

AU - Naghavi, Mohsen

AU - Nguyen, Binh Thanh

AU - Nirayo, Yirga Legesse

AU - Ogbo, Felix Akpojene

AU - Owolabi, Mayowa Ojo

AU - Pereira, David M.

AU - Postma, Maarten J.

AU - Qorbani, Mostafa

AU - Rahman, Muhammad Aziz

AU - Roba, Kedir T.

AU - Safari, Hosein

AU - Safiri, Saeid

AU - Satpathy, Maheswar

AU - Sawhney, Monika

AU - Shafieesabet, Azadeh

AU - Shiferaw, Mekonnen Sisay

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. Methods: Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. Findings: In 2016, 6·1 million (95% uncertainty interval [UI] 5·0–7·3) individuals had Parkinson's disease globally, compared with 2·5 million (2·0–3·0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21·7% (95% UI 18·1–25·3) over the same period (compared with an increase of 74·3%, 95% UI 69·2–79·6, for crude prevalence rates). Parkinson's disease caused 3·2 million (95% UI 2·6–4·0) DALYs and 211 296 deaths (95% UI 167 771–265 160) in 2016. The male-to-female ratios of age-standardised prevalence rates were similar in 2016 (1·40, 95% UI 1·36–1·43) and 1990 (1·37, 1·34–1·40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. Interpretation: Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially. Funding: Bill & Melinda Gates Foundation.

AB - Background: Neurological disorders are now the leading source of disability globally, and ageing is increasing the burden of neurodegenerative disorders, including Parkinson's disease. We aimed to determine the global burden of Parkinson's disease between 1990 and 2016 to identify trends and to enable appropriate public health, medical, and scientific responses. Methods: Through a systematic analysis of epidemiological studies, we estimated global, regional, and country-specific prevalence and years of life lived with disability for Parkinson's disease from 1990 to 2016. We estimated the proportion of mild, moderate, and severe Parkinson's disease on the basis of studies that used the Hoehn and Yahr scale and assigned disability weights to each level. We jointly modelled prevalence and excess mortality risk in a natural history model to derive estimates of deaths due to Parkinson's disease. Death counts were multiplied by values from the Global Burden of Disease study's standard life expectancy to compute years of life lost. Disability-adjusted life-years (DALYs) were computed as the sum of years lived with disability and years of life lost. We also analysed results based on the Socio-demographic Index, a compound measure of income per capita, education, and fertility. Findings: In 2016, 6·1 million (95% uncertainty interval [UI] 5·0–7·3) individuals had Parkinson's disease globally, compared with 2·5 million (2·0–3·0) in 1990. This increase was not solely due to increasing numbers of older people, because age-standardised prevalence rates increased by 21·7% (95% UI 18·1–25·3) over the same period (compared with an increase of 74·3%, 95% UI 69·2–79·6, for crude prevalence rates). Parkinson's disease caused 3·2 million (95% UI 2·6–4·0) DALYs and 211 296 deaths (95% UI 167 771–265 160) in 2016. The male-to-female ratios of age-standardised prevalence rates were similar in 2016 (1·40, 95% UI 1·36–1·43) and 1990 (1·37, 1·34–1·40). From 1990 to 2016, age-standardised prevalence, DALY rates, and death rates increased for all global burden of disease regions except for southern Latin America, eastern Europe, and Oceania. In addition, age-standardised DALY rates generally increased across the Socio-demographic Index. Interpretation: Over the past generation, the global burden of Parkinson's disease has more than doubled as a result of increasing numbers of older people, with potential contributions from longer disease duration and environmental factors. Demographic and potentially other factors are poised to increase the future burden of Parkinson's disease substantially. Funding: Bill & Melinda Gates Foundation.

UR - http://www.scopus.com/inward/record.url?scp=85055021376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055021376&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(18)30295-3

DO - 10.1016/S1474-4422(18)30295-3

M3 - Article

C2 - 30287051

AN - SCOPUS:85055021376

VL - 17

SP - 939

EP - 953

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 11

ER -